Fibroblast growth factor receptor 2: Expression, roles, and potential as a novel molecular target for colorectal cancer

Pathology Research International

Volumn 2012, Issue , 2012, Pages

  Matsuda, Yoko ^a   Ueda, Junji ^a   Ishiwata, Toshiyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866262456     PISSN: None     EISSN: 2042003X     Source Type: Journal    
DOI: 10.1155/2012/574768     Document Type: Review

References (79)

1. Siegel R., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA-Cancer Journal for Clinicians 2011 61 4 212 236
2. Chau I., Cunningham D., Treatment in advanced colorectal cancer: what, when and how? British Journal of Cancer 2009 100 11 1704 1719 2-s2.0-67349152647 10.1038/sj.bjc.6605061
3. Itoh N., The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biological and Pharmaceutical Bulletin 2007 30 10 1819 1825 2-s2.0-35349007958 10.1248/bpb.30.1819 (Pubitemid 47607758)
4. Itoh N., Ornitz D. M., Evolution of the Fgf and Fgfr gene families. Trends in Genetics 2004 20 11 563 569 2-s2.0-4744372082 10.1016/j.tig.2004.08. 007 (Pubitemid 39314564)
5. Katoh M., Katoh M., FGF signaling network in the gastrointestinal tract (Review). International Journal of Oncology 2006 29 1 163 168 2-s2.0-33751113439
6. Jayson G. C., Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. International Journal of Cancer 1999 82 2 298 304 (Pubitemid 29293792)
7. Spinola M., Leoni V. P., Tanuma J. I., Pettinicchio A., Frattini M., Signoroni S., Agresti R., Giovanazzi R., Pilotti S., Bertario L., Ravagnani F., Dragani T. A., FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncology Reports 2005 14 2 415 419 2-s2.0-24744451851
8. Jang J. H., Shin K. H., Park J. G., Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Research 2001 61 9 3541 3543 2-s2.0-0035328856
9. Sato T., Oshima T., Yoshihara K., Yamamoto N., Yamada R., Nagano Y., Fujii S., Kunisaki C., Shiozawa M., Akaike M., Rino Y., Tanaka K., Masuda M., Imada T., Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncology Reports 2009 21 1 211 216 2-s2.0-61449341860 10.3892/or00000210
10. Yoshino M., Ishiwata T., Watanabe M., Komine O., Shibuya T., Tokunaga A., Naito Z., Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer. Oncology Reports 2005 13 2 247 252 2-s2.0-16244416568
11. Sonvilla G., Allerstorfer S., Heinzle C., Stättner S., Karner J., Klimpfinger M., Wrba F., Fischer H., Gauglhofer C., Spiegl-Kreinecker S., Grasl-Kraupp B., Holzmann K., Grusch M., Berger W., Marian B., Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. British Journal of Cancer 2010 102 7 1145 1156 2-s2.0-77950369707 10.1038/sj.bjc. 6605596
12. Easton D. F., Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007 447 7148 1087 1093 (Pubitemid 47014426)
13. Hunter D. J., Kraft P., Jacobs K. B., Cox D. G., Yeager M., Hankinson S. E., Wacholder S., Wang Z., Welch R., Hutchinson A., Wang J., Yu K., Chatterjee N., Orr N., Willett W. C., Colditz G. A., Ziegler R. G., Berg C. D., Buys S. S., McCarty C. A., Feigelson H. S., Calle E. E., Thun M. J., Hayes R. B., Tucker M., Gerhard D. S., Fraumeni J. F., Hoover R. N., Thomas G., Chanock S. J., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics 2007 39 7 870 874 2-s2.0-34250001297 10.1038/ng2075 (Pubitemid 47014500)
14. McGrath M., Lee I. M., Buring J., Hunter D. J., De Vivo I., Novel breast cancer risk alleles and endometrial cancer risk. International Journal of Cancer 2008 123 12 2961 2964 2-s2.0-57349198006 10.1002/ijc.23862
15. Byron S. A., Gartside M. G., Wellens C. L., Mallon M. A., Keenan J. B., Powell M. A., Goodfellow P. J., Pollock P. M., Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Research 2008 68 17 6902 6907 2-s2.0-52049086201 10.1158/0008-5472.CAN-08-0770
16. Byron S. A., Pollock P. M., FGFR2 as a molecular target in endometrial cancer. Future Oncology 2009 5 1 27 32 2-s2.0-65349087952 10.2217/14796694.5.1. 27
17. Katoh Y., Katoh M., FGFR2-related pathogenesis and FGFR2-targeted therapeutics (review). International Journal of Molecular Medicine 2009 23 3 307 311 2-s2.0-64249151246 10.3892/ijmm00000132
18. Katoh M., Cancer genomics and genetics of FGFR2 (Review). International Journal of Oncology 2008 33 2 233 237 2-s2.0-48749094526 10.3892/ijo00000001
19. Eswarakumar V. P., Lax I., Schlessinger J., Cellular signaling by fibroblast growth factor receptors. Cytokine and Growth Factor Reviews 2005 16 2 139 149 2-s2.0-18144383021 10.1016/j.cytogfr.2005.01.001 (Pubitemid 40616112)
20. Hovhannisyan R. H., Warzecha C. C., Carstens R. P., Characterization of sequences and mechanisms through which ISE/ISS-3 regulates FGFR2 splicing. Nucleic Acids Research 2006 34 1 373 385 2-s2.0-31544441973 10.1093/nar/gkj407 (Pubitemid 43160060)
21. Baraniak A. P., Chen J. R., Garcia-Blanco M. A., Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Molecular and Cellular Biology 2006 26 4 1209 1222 2-s2.0-32044467372 10.1128/MCB.26.4.1209-1222.2006 (Pubitemid 43202550)
22. Warzecha C. C., Sato T. K., Nabet B., Hogenesch J. B., Carstens R. P., ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Molecular Cell 2009 33 5 591 601 2-s2.0-61649087689 10.1016/j.molcel.2009.01.025
23. Hovhannisyan R. H., Carstens R. P., A novel intronic cis element, ISE/ISS-3, regulates rat fibroblast growth factor receptor 2 splicing through activation of an upstream exon and repression of a downstream exon containing a noncanonical branch point sequence. Molecular and Cellular Biology 2005 25 1 250 263 2-s2.0-11144328200 10.1128/MCB.25.1.250-263.2005 (Pubitemid 40039816)
24. Orr-Urtreger A., Bedford M. T., Burakova T., Arman E., Zimmer Y., Yayon A., Givol D., Lonai P., Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Developmental Biology 1993 158 2 475 486 2-s2.0-0027199056 10.1006/dbio.1993.1205 (Pubitemid 23243904)
25. Ibrahimi O. A., Eliseenkova A. V., Plotnikov A. N., Yu K., Ornitz D. M., Mohammadi M., Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proceedings of the National Academy of Sciences of the United States of America 2001 98 13 7182 7187 2-s2.0-0035912715 10.1073/pnas.121183798 (Pubitemid 32567923)
26. Mohammadi M., Olsen S. K., Ibrahimi O. A., Structural basis for fibroblast growth factor receptor activation. Cytokine and Growth Factor Reviews 2005 16 2 107 137 2-s2.0-18144423534 10.1016/j.cytogfr.2005.01.008 (Pubitemid 40616111)
27. Friesel R. E., Maciag T., Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB Journal 1995 9 10 919 925 2-s2.0-0029143960
28. Kouhara H., Hadari Y. R., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., Schlessinger J., A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997 89 5 693 702 2-s2.0-0030706168 (Pubitemid 27516172)
29. Itoh H., Hattori Y., Sakamoto H., Ishii H., Kishi T., Sasaki H., Yoshida T., Koono M., Sugimura T., Terada M., Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Research 1994 54 12 3237 3241 2-s2.0-0028305121 (Pubitemid 24208935)
30. Cha J. Y., Lambert Q. T., Reuther G. W., Der C. J., Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Molecular Cancer Research 2008 6 3 435 445 2-s2.0-40949090037 10.1158/1541-7786.MCR-07-0187 (Pubitemid 351416534)
31. Zhu X., Asa S. L., Ezzat S., Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Molecular Endocrinology 2009 23 9 1397 1405 2-s2.0-69449083319 10.1210/me.2009-0071
32. Davies H., Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Research 2005 65 17 7591 7595 (Pubitemid 41297230)
33. Pollock P. M., Gartside M. G., Dejeza L. C., Powell M. A., Mallon M. A., Davies H., Mohammadi M., Futreal P. A., Stratton M. R., Trent J. M., Goodfellow P. J., Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007 26 50 7158 7162 2-s2.0-34250829395 10.1038/sj.onc. 1210529 (Pubitemid 350059681)
34. Adnane J., Gaudray P., Dionne C. A., Crumley G., Jaye M., Schlessinger J., Jeanteur P., Birnbaum D., Theillet C., BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991 6 4 659 663 2-s2.0-0025778485 (Pubitemid 21924133)
35. Gartside M. G., Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Molecular Cancer Research 2009 7 1 41 54
36. Carstens R. P., Eaton J. V., Krigman H. R., Walther P. J., Garcia-Blanco M. A., Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997 15 25 3059 3065 2-s2.0-0031577732 (Pubitemid 28043485)
37. Chaffer C. L., Dopheide B., Savagner P., Thompson E. W., Williams E. D., Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007 75 9 831 842 2-s2.0-36048942703 10.1111/j.1432-0436.2007.00210.x (Pubitemid 350086171)
38. Chaffer C. L., Brennan J. P., Slavin J. L., Blick T., Thompson E. W., Williams E. D., Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Research 2006 66 23 11271 11278 2-s2.0-33845809125 10.1158/0008-5472.CAN-06-2044 (Pubitemid 46009956)
39. Oltean S., Sorg B. S., Albrecht T., Bonano V. I., Brazas R. M., Dewhirst M. W., Garcia-Blanco M. A., Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostrate tumors reveals unexpected epithelial mesenchymal plasticity. Proceedings of the National Academy of Sciences of the United States of America 2006 103 38 14116 14121 2-s2.0-33749025816 10.1073/pnas.0603090103 (Pubitemid 44452989)
40. Kawase T., Matsuo K., Suzuki T., Hiraki A., Watanabe M., Iwata H., Tanaka H., Tajima K., FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. International Journal of Cancer 2009 125 8 1946 1952 2-s2.0-70349245552 10.1002/ijc.24505
41. Luqmani Y. A., Graham M., Coombes R. C., Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. British Journal of Cancer 1992 66 2 273 280 2-s2.0-0026696081
42. Ishikawa A., Kudo M., Nakazawa N., Onda M., Ishiwata T., Takeshita T., Naito Z., Expression of keratinocyte growth factor and its receptor in human endometrial cancer in cooperation with steroid hormones. International Journal of Oncology 2008 32 3 565 574 2-s2.0-40249118869 (Pubitemid 351330462)
43. Kurban G., Ishiwata T., Kudo M., Yokoyama M., Sugisaki Y., Naito Z., Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncology Reports 2004 11 5 987 991 2-s2.0-16544378971
44. Kawase R., Ishiwata T., Matsuda Y., Onda M., Kudo M., Takeshita T., Naito Z., Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. International Journal of Oncology 2010 36 2 331 340 2-s2.0-75449096965 10.3892/ijo-00000504
45. Yamayoshi T., Nagayasu T., Matsumoto K., Abo T., Hishikawa Y., Koji T., Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. Journal of Pathology 2004 204 1 110 118 2-s2.0-4544233936 10.1002/path.1617 (Pubitemid 39214488)
46. Yoshino M., Ishiwata T., Watanabe M., Matsunobu T., Komine O., Ono Y., Yamamoto T., Fujii T., Matsumoto K., Tokunaga A., Naito Z., Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. International Journal of Oncology 2007 31 4 721 728 2-s2.0-35848969343
47. Matsunobu T., Ishiwata T., Yoshino M., Watanabe M., Kudo M., Matsumoto K., Tokunaga A., Tajiri T., Naito Z., Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer. International Journal of Oncology 2006 28 2 307 314 2-s2.0-33750980657
48. Ishiwata T., Friess H., Büchler M. W., Lopez M. E., Korc M., Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. American Journal of Pathology 1998 153 1 213 222 2-s2.0-0031872092 (Pubitemid 28317524)
49. Cho K., Ishiwata T., Uchida E., Nakazawa N., Korc M., Naito Z., Tajiri T., Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. American Journal of Pathology 2007 170 6 1964 1974 2-s2.0-34447318647 10.2353/ajpath.2007.060935 (Pubitemid 47339270)
50. Watanabe M., Ishiwata T., Nishigai K., Moriyama Y., Asano G., Overexpression of keratinocyte growth factor in cancer cells and enterochromaffin cells in human colorectal cancer. Pathology International 2000 50 5 363 372 2-s2.0-0033948164 10.1046/j.1440-1827.2000.01054.x (Pubitemid 30451479)
51. Matsuike A., Ishiwata T., Watanabe M., Asano G., Expression of fibroblast growth factor (FGF)-10 in human colorectal adenocarcinoma cells. Journal of Nippon Medical School 2001 68 5 397 404 2-s2.0-0035490428
52. Nomura S., Yoshitomi H., Takano S., Shida T., Kobayashi S., Ohtsuka M., Kimura F., Shimizu H., Yoshidome H., Kato A., Miyazaki M., FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. British Journal of Cancer 2008 99 2 305 313 2-s2.0-48249126223 10.1038/sj.bjc.6604473
53. Matsuda Y., Ishiwata T., Yamahatsu K., Kawahara K., Hagio M., Peng W. X., Yamamoto T., Nakazawa N., Seya T., Ohaki Y., Naito Z., Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer. Cancer Letters 2011 309 2 209 219 2-s2.0-79960845455 10.1016/j.canlet.2011.06.009
54. Visco V., Belleudi F., Marchese C., Leone L., Aimati L., Cardinali G., Kovacs D., Frati L., Torrisi M. R., Differential response to keratinocyte growth factor receptor and epidermal growth factor receptor ligands of proliferating and differentiating intestinal epithelial cells. Journal of Cellular Physiology 2004 200 1 31 44 2-s2.0-2642532099 10.1002/jcp.10385 (Pubitemid 38720619)
55. Otte J. M., Expression of keratinocyte growth factor and its receptor in colorectal cancer. European Journal of Clinical Investigation 2000 30 3 222 229
56. Narita K., Fujii T., Ishiwata T., Yamamoto T., Kawamoto Y., Kawahara K., Nakazawa N., Naito Z., Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells. International Journal of Oncology 2009 34 2 355 360 2-s2.0-64549087241 10.3892/ijo00000158
57. Kudo M., Ishiwata T., Nakazawa N., Kawahara K., Fujii T., Teduka K., Naito Z., Keratinocyte growth factor-transfection-stimulated adhesion of colorectal cancer cells to extracellular matrices. Experimental and Molecular Pathology 2007 83 3 443 452 2-s2.0-36048990837 10.1016/j.yexmp.2007.07.001 (Pubitemid 350087022)
58. Ishiwata T., Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. American Journal of Pathology 2012 180 5 1928 1941
59. Amano R., Yamada N., Doi Y., Yashiro M., Ohira M., Miwa A., Hirakawa K., Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer. Anticancer Research 2010 30 10 4115 4121 2-s2.0-78650231488
60. Nakamura K., Yashiro M., Matsuoka T., Tendo M., Shimizu T., Miwa A., Hirakawa K., A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 2006 131 5 1530 1541 2-s2.0-33750701827 10.1053/j.gastro.2006. 08.030 (Pubitemid 44708935)
61. Yashiro M., Shinto O., Nakamura K., Tendo M., Matsuoka T., Matsuzaki T., Kaizaki R., Miwa A., Hirakawa K., Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. International Journal of Cancer 2010 126 4 1004 1016 2-s2.0-74049083220 10.1002/ijc.24763
62. Sakurai K., Yamada N., Yashiro M., Matsuzaki T., Komatsu M., Ohira M., Miwa A., Hirakawa K., A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. European Journal of Cancer 2007 43 17 2612 2620 2-s2.0-36049046092 10.1016/j.ejca.2007.09.002 (Pubitemid 350086941)
63. Zhao W. M., Wang L., Park H., Chhim S., Tanphanich M., Yashiro M., Kim K. J., Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clinical Cancer Research 2010 16 23 5750 5758 2-s2.0-78650331674 10.1158/1078-0432.CCR-10-0531
64. Wang J., Antitumor activity of a recombinant soluble ectodomain of mutant human fibroblast growth factor receptor-2 IIIc. Molecular Cancer Therapeutics 2011 10 9 1656 1666
65. Gonzalez A. M., Hill D. J., Logan A., Maher P. A., Baird A., Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus. Pediatric Research 1996 39 3 375 385 2-s2.0-0030070238 (Pubitemid 26070827)
66. Kirikoshi H., Sagara N., Saitoh T., Tanaka K., Sekihara H., Shiokawa K., Katoh M., Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3-p22. Biochemical and Biophysical Research Communications 2000 274 2 337 343 2-s2.0-0034596239 10.1006/bbrc.2000.3142 (Pubitemid 30614320)
67. Jeffers M., McDonald W. F., Chillakuru R. A., Yang M., Nakase H., Deegler L. L., Sylander E. D., Rittman B., Bendele A., Sartor R. B., Lichenstein H. S., A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 2002 123 4 1151 1162 2-s2.0-0036788241 10.1053/gast.2002.36041
68. Jang J. H., Shin K. H., Park Y. J., Lee R. J., McKeehan W. L., Park J. G., Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Research 2000 60 15 4049 4052 2-s2.0-0033900046 (Pubitemid 30636582)
69. Desnoyers L. R., Pai R., Ferrando R. E., Hötzel K., Le T., Ross J., Carano R., D'Souza A., Qing J., Mohtashemi I., Ashkenazi A., French D. M., Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008 27 1 85 97 2-s2.0-37849029159 10.1038/sj.onc.1210623
70. Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T., Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochemical and Biophysical Research Communications 2000 267 2 658 662 2-s2.0-0034685038 10.1006/bbrc.1999.2010 (Pubitemid 30076854)
71. Noble M. E. M., Endicott J. A., Johnson L. N., Protein kinase inhibitors: insights into drug design from structure. Science 2004 303 5665 1800 1805 2-s2.0-1642323740 10.1126/science.1095920 (Pubitemid 38374863)
72. Krause D. S., Van Etten R. A., Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine 2005 353 2 172 187 2-s2.0-22044442973 10.1056/NEJMra044389 (Pubitemid 41058349)
73. Katoh M., Katoh M., Bioinformatics for cancer management in the post-genome era. Technology in Cancer Research and Treatment 2006 5 2 169 175 2-s2.0-33645961885
74. Zheng S. J., Zheng S. P., Huang F. Y., Jiao C. L., Wu R. L., Synergistic anti-tumor effect of recombinant chicken fibroblast growth receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model. World Journal of Gastroenterology 2007 13 17 2484 2489 2-s2.0-34250625645
75. Ohta M., Kawabata T., Yamamoto M., Tanaka T., Kikuchi H., Hiramatsu Y., Kamiya K., Baba M., Konno H., TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surgery Today 2009 39 12 1046 1053 2-s2.0-72949117051 10.1007/s00595-009-4020-y
76. Ayers M., Fargnoli J., Lewin A., Wu Q., Suso Platero J., Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Research 2007 67 14 6899 6906 2-s2.0-34547100778 10.1158/0008-5472.CAN-06-4555 (Pubitemid 47105537)
77. Tentler J. J., Bradshaw-Pierce E. L., Serkova N. J., Hasebroock K. M., Pitts T. M., Diamond J. R., Fletcher G. C., Bray M. R., Eckhardt S. G., Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clinical Cancer Research 2010 16 11 2989 2998 2-s2.0-77953116873 10.1158/1078-0432.CCR-10-0325
78. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., Marsters S., Stawicki S., Tien J., Totpal K., Ross S., Stinson S., Dornan D., French D., Wang Q. R., Stephan J. P., Wu Y., Wiesmann C., Ashkenazi A., Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. Journal of Clinical Investigation 2009 119 5 1216 1229 2-s2.0-66349135677 10.1172/JCI38017
79. Martínez-Torrecuadrada J. L., Cheung L. H., López-Serra P., Barderas R., Caamero M., Ferreiro S., Rosenblum M. G., Casal J. I., Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Molecular Cancer Therapeutics 2008 7 4 862 873 2-s2.0-42249103255 10.1158/1535-7163.MCT- 07-0394 (Pubitemid 351551039)